Rigel Pharmaceuticals | RIGL - Net Income


Rigel Pharmaceuticals reported $12.42M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Agenus USD 39.17M 49.8M Mar/2026
Amgen USD 2.38B 556M Jun/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -194.28M 61.55M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Celldex Therapeutics USD -73.5M 5.18M Jun/2026
Daiichi Sankyo JPY 68.64B 18B Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Halozyme Therapeutics USD 229.91M 79.86M Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Ligand Pharmaceuticals USD 48.51M 61.85M Jun/2026
MacroGenics USD -36.77M 22.62M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Veracyte USD 25.49M 3.22M Jun/2026